These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 31209181)

  • 1. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
    Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
    Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumoral microenvironment prevents de novo asparagine biosynthesis in B cell lymphoma, regardless of ASNS expression.
    Grima-Reyes M; Vandenberghe A; Nemazanyy I; Meola P; Paul R; Reverso-Meinietti J; Martinez-Turtos A; Nottet N; Chan WK; Lorenzi PL; Marchetti S; Ricci JE; Chiche J
    Sci Adv; 2022 Jul; 8(27):eabn6491. PubMed ID: 35857457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.
    Chan WK; Lorenzi PL; Anishkin A; Purwaha P; Rogers DM; Sukharev S; Rempe SB; Weinstein JN
    Blood; 2014 Jun; 123(23):3596-606. PubMed ID: 24659632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines.
    Su N; Pan YX; Zhou M; Harvey RC; Hunger SP; Kilberg MS
    Pediatr Blood Cancer; 2008 Feb; 50(2):274-9. PubMed ID: 17514734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.
    Panosyan EH; Wang Y; Xia P; Lee WN; Pak Y; Laks DR; Lin HJ; Moore TB; Cloughesy TF; Kornblum HI; Lasky JL
    Mol Cancer Res; 2014 May; 12(5):694-702. PubMed ID: 24505127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
    Sugimoto K; Suzuki HI; Fujimura T; Ono A; Kaga N; Isobe Y; Sasaki M; Taka H; Miyazono K; Komatsu N
    Cancer Sci; 2015 Nov; 106(11):1534-43. PubMed ID: 26331698
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Van Trimpont M; Schalk AM; De Visser Y; Nguyen HA; Reunes L; Vandemeulebroecke K; Peeters E; Su Y; Lee H; Lorenzi PL; Chan WK; Mondelaers V; De Moerloose B; Lammens T; Goossens S; Van Vlierberghe P; Lavie A
    Haematologica; 2023 Feb; 108(2):409-419. PubMed ID: 35979719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias
    Nguyen HA; Su Y; Zhang JY; Antanasijevic A; Caffrey M; Schalk AM; Liu L; Rondelli D; Oh A; Mahmud DL; Bosland MC; Kajdacsy-Balla A; Peirs S; Lammens T; Mondelaers V; De Moerloose B; Goossens S; Schlicht MJ; Kabirov KK; Lyubimov AV; Merrill BJ; Saunthararajah Y; Van Vlierberghe P; Lavie A
    Cancer Res; 2018 Mar; 78(6):1549-1560. PubMed ID: 29343523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
    Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
    Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells.
    Aslanian AM; Kilberg MS
    Biochem J; 2001 Aug; 358(Pt 1):59-67. PubMed ID: 11485552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asparaginase pharmacology: challenges still to be faced.
    Lanvers-Kaminsky C
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):439-450. PubMed ID: 28197753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies.
    Ardalan N; Mirzaie S; Sepahi AA; Khavari-Nejad RA
    Med Hypotheses; 2018 Mar; 112():7-17. PubMed ID: 29447943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-asparaginase anti-tumor activity in pancreatic cancer is dependent on its glutaminase activity and resistance is mediated by glutamine synthetase.
    Blachier J; Cleret A; Guerin N; Gil C; Fanjat JM; Tavernier F; Vidault L; Gallix F; Rama N; Rossignol R; Piedrahita D; Andrivon A; Châlons-Cottavoz M; Aguera K; Gay F; Horand F; Laperrousaz B
    Exp Cell Res; 2023 May; 426(2):113568. PubMed ID: 36967104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
    Panosyan EH; Grigoryan RS; Avramis IA; Seibel NL; Gaynon PS; Siegel SE; Fingert HJ; Avramis VI
    Anticancer Res; 2004; 24(2C):1121-5. PubMed ID: 15154634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sulfoximine-based inhibitor of human asparagine synthetase kills L-asparaginase-resistant leukemia cells.
    Ikeuchi H; Ahn YM; Otokawa T; Watanabe B; Hegazy L; Hiratake J; Richards NG
    Bioorg Med Chem; 2012 Oct; 20(19):5915-27. PubMed ID: 22951255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells.
    Nishikawa G; Kawada K; Hanada K; Maekawa H; Itatani Y; Miyoshi H; Taketo MM; Obama K
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding targets for a metabolic therapy of cancer: L-asparaginase.
    Covini D; Tardito S; Bussolati O; Chiarelli LR; Pasquetto MV; Digilio R; Valentini G; Scotti C
    Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):4-13. PubMed ID: 21854356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
    Avramis VI; Tiwari PN
    Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.
    Chien WW; Le Beux C; Rachinel N; Julien M; Lacroix CE; Allas S; Sahakian P; Cornut-Thibaut A; Lionnard L; Kucharczak J; Aouacheria A; Abribat T; Salles G
    Sci Rep; 2015 Jan; 5():8068. PubMed ID: 25626693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.